复方乳酸杆菌治疗幽门螺杆菌临床疗效观察

Observation on Clinical Effect of Compound Lactobacillus in Treatment of Helicobacter Pylori

目的探讨用微生物制剂治疗幽门螺旋杆菌(HP)的效果。方法选取我院检测幽门螺旋杆菌阳性病人160例,随机分成两组。治疗组用复方乳酸杆菌联合替普瑞酮治疗一个月。对照组用常规质子泵抑制剂(PPI)方案治疗7d。疗程结束后分别行胃镜病理活检及14C呼气试验检测HP,比较两组治疗方案的HP根除率。结果治疗组根除率87.75%,对照组根除率76.92%,两组比较差异无显著性,P>0.05。结论微生物制剂治疗幽门螺旋杆菌感染方面的作用与抗菌药相似,可进一步扩大总结与应用。

OBJECTIVE To investigate the efficacy of microbiological preparation in helicobacter pylori therapy. METHODS 160 helicobacter pylori （HP）-positive patients were randomly divided into the compound lactobacillus group （compound lactobacillus and teprenone for one month） and PPI group（PPI for 7 d）. After treatment, endoscopic mucosal resection and ^14C-urea breath test were used to compare HP eradication rate of the two groups. RESULTS The eradication rate of compound lactobacillus group and control were 87.75% and 76.92%, with no statistical difference （P〉0.05）. CONCLUSION Our results suggest that microbiological preparation is similar to antibacterial in helicobacter pylori infection therapy, deserving further application.